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Abstract
 
The firm adhesion and transplatelet migration of leukocytes on vascular thrombus are both de-
pendent on the interaction of the leukocyte integrin, Mac-1, and a heretofore unknown platelet
 
counterreceptor. Here, we identify the platelet counterreceptor as glycoprotein (GP) Ib
 
a
 
, a
component of the GP Ib-IX-V complex, the platelet von Willebrand factor (vWf) receptor.
THP-1 monocytic cells and transfected cells that express Mac-1 adhered to GP Ib
 
a
 
–coated wells.
Inhibition studies with monoclonal antibodies or receptor ligands showed that the interaction in-
volves the Mac-1 I domain (homologous to the vWf A1 domain), and the GP Ib
 
a
 
 leucine-rich
repeat and COOH-terminal flanking regions. The specificity of the interaction was confirmed
by the finding that neutrophils from wild-type mice, but not from Mac-1–deficient mice, bound
to purified GP Ib
 
a
 
 and to adherent platelets, the latter adhesion being inhibited by pretreatment
of the platelets with mocarhagin, a protease that specifically cleaves GP Ib
 
a
 
. Finally, immobilized
GP Ib
 
a
 
 supported the rolling and firm adhesion of THP-1 cells under conditions of flow. These
observations provide a molecular target for disrupting leukocyte–platelet complexes that promote
vascular inflammation in thrombosis, atherosclerosis, and angioplasty-related restenosis.
Key words: inﬂammation • leukocytes • platelets • adhesion • receptors
 
Introduction
 
Adhesive interactions between vascular cells play impor-
tant roles in orchestrating the inflammatory response. Re-
cruitment of circulating leukocytes to vascular endothe-
lium requires multistep adhesive and signaling events
including selectin-mediated attachment and rolling, leuko-
cyte activation, and integrin-mediated firm adhesion and
diapedesis that result in the infiltration of inflammatory
cells into the blood vessel wall (1). Firm attachment is me-
diated by members of the 
 
b
 
2 integrin family, LFA-1
(
 
a
 
L
 
b
 
2, CD11a/CD18), Mac-1 (
 
a
 
M
 
b
 
2, CD11b/CD18),
and p150,95 (
 
a
 
X
 
b
 
2, CD11c/CD18), which bind to endo-
thelial counterligands (e.g., intercellular adhesion molecule 1
[ICAM-1]
 
1
 
) (2), to endothelial-associated extracellular
matrix proteins (e.g., fibrinogen) (3), or to glycosamino-
glycans (4).
Leukocyte recruitment and infiltration also occur at sites
of vascular injury where the lining endothelial cells have
been denuded and platelets and fibrin have been deposited.
In vivo studies show that leukocytes and platelets colocalize
at sites of hemorrhage, within atherosclerotic and postan-
gioplasty restenotic lesions, and in areas of ischemia-reper-
fusion injury (5–8). This heterotypic interaction between
platelets and leukocytes links the hemostatic/thrombotic
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Abbreviations used in this paper:
 
 BSS, Bernard-Soulier syndrome; GP, gly-
coprotein; IC
 
50
 
, 50% inhibitory concentration; ICAM-1, intercellular ad-
hesion molecule 1; RGDS, arginine-glycine-aspartate-serine; TRAP,
thrombin receptor activating peptide; vWf, von Willebrand factor. 
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and inflammatory responses (5). Although less well charac-
terized, a similar sequential adhesion model of leukocyte
attachment to and transmigration across surface-adherent
platelets has been proposed (9–14). The initial tethering
and rolling of leukocytes on platelet P-selectin (9, 10, 15)
are followed by their firm adhesion and transplatelet migra-
tion, processes that are dependent on the leukocyte inte-
grin, Mac-1 (12–14). In addition to promoting the accu-
mulation of leukocytes at sites of platelet coverage within
the vasculature, the binding of platelets to neutrophils in-
fluences key cellular effector responses by inducing neutro-
phil activation, upregulating expression of cell adhesion
molecules (16), and generating signals that promote inte-
grin activation (13), chemokine synthesis (17, 18), and the
respiratory burst (16). Interestingly, both neutrophil–plate-
let and monocyte–platelet aggregates have been identified
in the peripheral blood of patients with coronary artery dis-
ease (16, 19) and may be markers of disease activity (16).
Leukocyte Mac-1 binds endothelial cell adhesion mole-
cules of the immunoglobulin superfamily, most promi-
nently ICAM-1. This receptor is not found on platelets, al-
though platelets express a related receptor, ICAM-2 (20).
Nevertheless, Diacovo et al. (12) have shown that ICAM-2
blockade has no effect on the firm adhesion of neutrophils
on monolayers of activated platelets under flow. Because
activated Mac-1 binds fibrinogen, one possibility is that
firm adhesion is mediated by Mac-1 binding to fibrinogen
that has been immobilized on platelet glycoprotein (GP)
IIb-IIIa (
 
a
 
IIb
 
b
 
3
 
). Indeed, Weber and Springer (21) found
that neutrophil adhesion to activated platelets under flow
was partially blocked by an antibody against GP IIb-IIIa and
that platelets from a patient with Glanzmann thrombasthe-
nia (which lack GP IIb-IIIa) did not support neutrophil ac-
cumulation nearly as well as did wild-type platelets. Never-
theless, neither of these manipulations was successful in
completely blocking neutrophil accumulation, even in con-
junction with ICAM-2–blocking antibodies. Against a role
for the Mac-1–fibrinogen–GP IIb-IIIa axis in neutrophil ar-
rest, Ostrovsky et al. (22) found that neither arginine-gly-
cine-aspartate-serine (RGDS) peptides nor the replacement
of normal platelets with thrombasthenic platelets affected
the accumulation of the leukocytes on platelets. Despite the
differences in the two studies, both groups proposed the ex-
istence of another Mac-1 receptor on the platelet surface.
Evaluation of the structural features of integrins has pro-
vided us with insights into a candidate platelet counter-
receptor for Mac-1. Integrins are heterodimeric proteins
composed of one 
 
a
 
 and one 
 
b
 
 subunit (23). A subset of in-
tegrin 
 
a
 
 subunits, including CD11b of Mac-1, contains an
inserted domain (I domain) of 
 
z
 
200 amino acids that is
implicated in ligand binding (24–28) and is strikingly simi-
lar to the A domains of von Willebrand factor (vWf) (29–
31), one of which, A1, mediates the interaction of vWf
with its platelet receptor, the GP Ib-IX-V complex.
Through this interaction, platelets are able to adhere to re-
gions of vascular injury in a process entirely analogous to
the interaction between leukocytes and activated endothe-
lium. Platelets recognize vWf in the subendothelium, and
 
roll along the region until they become activated and ad-
here firmly through GP IIb-IIIa (32).
One interesting aspect of the GP Ib-IX-V–vWf interac-
tion is that both platelets and vWf circulate freely in blood,
but do not interact unless vWf is immobilized on the sub-
endothelium or in the presence of very high shear stresses
(such as might be found at sites of arterial stenosis). Under
static conditions in vitro, the interaction requires the pres-
ence of modulators: botrocetin, a snake venom protein, or
ristocetin, a peptide antibiotic from the soil bacterium 
 
No-
cardia lurida
 
 (33). The modulators induce conformational
changes in vWf (and possibly also in GP Ib
 
a
 
, in the case of
ristocetin) that enable the interaction.
The GP Ib-IX-V complex comprises four phylogeneti-
cally related polypeptides, GP Ib
 
a
 
, GP Ib
 
b
 
, GP IX, and
GP V, of which only GP Ib
 
a
 
 has been shown to bind
ligands (34). The ligand-binding domain of this polypep-
tide resides within the NH
 
2
 
-terminal 300 amino acids, a re-
gion containing seven 24–amino acid leucine-rich repeats,
which assign this polypeptide to a large protein superfamily
with similar motifs. This region is held above the platelet
membrane by a heavily 
 
O
 
-glycosylated mucin-like region
called the macroglycopeptide. Following a single trans-
membrane domain, a cytoplasmic domain of 
 
z
 
100 amino
acids mediates association of the entire complex with the
cytoskeleton and with signaling proteins (33).
Because of the similarity of the vWf A1 domain and the
 
a
 
M I domain, we hypothesized that GP Ib
 
a
 
 might also be
able to bind Mac-1. Here, we report that GP Ib
 
a
 
 is a con-
stitutively expressed counterreceptor for Mac-1.
 
Materials and Methods
 
Materials.
 
Human fibrinogen depleted of plasminogen, vWf,
and fibronectin were purchased from Enzyme Research Labora-
tories. Porcine heparin (10,000 U/ml) was obtained from Elkins-
Sinn, Inc. TGF-
 
b
 
1 was from Collaborative Research, Inc., and
1,25-(OH)
 
2
 
 vitamin D
 
3
 
 was from Calbiochem. The snake venom
metalloprotease, mocarhagin, was purified as described previously
(35). Glycocalicin was purified by a minor modification of the
method of Canfield et al. (36) by successive chromatography on
wheat germ lectin Sepharose 6MB (Amersham Pharmacia Bio-
tech) and jacalin agarose (Pierce Chemical Co.) (Fig. 1). A 39/
34-kD dispase fragment of vWf encompassing the A1 domain
(Leu480–Gly718) was purified as described previously (37). Pep-
tide P2, corresponding to amino acid residues 377–395 in the 
 
g
 
chain of fibrinogen, which binds to the I domain of Mac-1 and
blocks fibrinogen binding (38), was obtained from the W.M.
Keck Biotechnology Resource Center (Yale University, New
Haven, CT). 2
 
9
 
,7
 
9
 
-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluo-
rescein, acetoxymethyl ester (BCECF AM) was purchased from
Molecular Probes.
CD11/CD18 mAbs used included the following: LPM19c, di-
rected to the 
 
a
 
M subunit of human Mac-1 (CD11b) and capable
of blocking fibrinogen, ICAM-1, and C3bi binding (a gift of Dr.
Karen Pulford, John Radcliffe Hospital, Oxford, UK) (24); M1/
70, directed to the 
 
a
 
M subunit of mouse Mac-1 (CD11b), with
broad ligand blocking properties (39; American Type Culture
Collection); TS1/22, directed to the 
 
a
 
L subunit of LFA-1
(CD11a) and capable of blocking ICAM binding (provided by Dr. 
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Lloyd Klickstein, Brigham and Women’s Hospital); and IB4, di-
rected to the common 
 
b
 
2 subunit (CD18; provided by Dr. Lloyd
Klickstein). The stimulating CD18 mAb KIM 127 was a gift of
Dr. Martyn Robinson (Celltech Ltd., Slough, England) (40).
The GP Ib
 
a
 
 mAbs used were: AK2, AP1, VM16d, SZ2, and
WM23. All but WM23 bind within the GP Ib
 
a
 
 ligand-binding
region, within the first 282 amino acids at the GP Ib
 
a
 
 NH
 
2
 
 ter-
minus. AK2 blocks vWf binding induced by both ristocetin and
botrocetin and binds within the first leucine-rich repeat (amino
acid residues 36–59). AP1 (provided by Dr. Dermot Kenny,
Beaumont Hospital, The Royal College of Surgeons, Dublin,
Ireland) also blocks both ristocetin- and botrocetin-induced vWf
binding (epitope 201–268); VM16d (gift of Dr. Alexey Mazurov,
Russian Ministry of Health, Moscow, Russia) only blocks botro-
cetin-induced vWf binding (epitope 201–268), as does SZ2
(epitope 269–282) (41). WM23 binds within the GP Ib
 
a
 
 macro-
glycopeptide and does not interfere with the binding of any GP
Ib
 
a
 
 ligands (42). The polyclonal GP Ib
 
a
 
 antibody was prepared
in rabbits immunized with glycocalicin (the soluble extracellular
region of GP Ib
 
a
 
) and affinity-purified over a glycocalicin Affigel
10/15 column (43).
7E3 and 10E5 (44), murine mAbs to GP IIb and/or IIIa that
block platelet fibrinogen binding, were provided by Dr. Barry S.
Coller (Mt. Sinai Medical Center, New York, NY). Y2/51
(Dako) is directed against CD61 (GP IIIa) and was purchased
conjugated to FITC. TUK4 (Dako) is directed against CD14 on
the monocyte surface and was purchased conjugated to PE. Y2/
51 and TUK4 are IgG murine antibodies. Murine IgG-FITC
(Dako) was used as a nonspecific isotype control. All mAbs were
purified unless otherwise indicated.
 
Cell Lines and Culture Conditions.
 
THP-1 monocytic cells
(American Type Culture Collection) were maintained in RPMI
1640 supplemented with 10% fetal bovine serum, 2 mM
glutamine, 25 mM Hepes, penicillin, and streptomycin. Differen-
tiation of THP-1 cells (10
 
6
 
/ml), which is accompanied by in-
creased expression of Mac-1, was induced by treatment with 1
ng/ml TGF-
 
b
 
1 and 50 nM 1,25-(OH)
 
2
 
 vitamin D
 
3
 
 (TGF-
 
b
 
/vit
D
 
3
 
) for 24 h (45). Nontransfected 293 cells (American Type Cul-
ture Collection) were maintained in DMEM/F12 supplemented
with 10% fetal bovine serum, 25 mM Hepes, penicillin, and strep-
tomycin; 293 cells expressing human LFA-1, Mac-1, or a chi-
meric LFA-1 receptor that contained the I domain of Mac-1 (i.e.,
LFA-1 [I
 
a
 
M]-transfected 293 cells), established as described previ-
ously (46–48), were maintained in similar media containing G418.
 
Preparation of Neutrophils and Platelets.
 
Mac-1–deficient (Mac-
1
 
2
 
/
 
2
 
) mice, generated as described previously (49), were back-
crossed for 
 
.
 
12 generations onto the C57BL/J6 strain. Murine
 
neutrophils were harvested from the peritoneal cavity of wild-
type C57BL/J6 (Mac-1
 
1
 
/
 
1
 
) or Mac-1
 
2
 
/
 
2
 
 mice by lavage with 10
ml RPMI 4 h after the intraperitoneal injection of 1 ml sterile 3%
thioglycollate broth. Isolated neutrophils were resuspended in
RPMI containing low-endotoxin BSA (0.5%). Cytospin prepara-
tions stained with Giemsa revealed that 
 
.
 
90% of the cells were
neutrophils. Cell viability (
 
.
 
95%) was assessed in all cases using
trypan blue exclusion.
Venous blood was obtained from volunteers who had not
consumed aspirin or other nonsteroidal antiinflammatory drugs
for at least 10 d, and was anticoagulated with 13 mM trisodium
citrate. Platelet-rich plasma was prepared by centrifugation at 150 
 
g
 
for 10 min. Gel-filtered platelets were obtained by passage of
platelet-rich plasma over a Sepharose 2B column in calcium-free
Tyrode’s Hepes buffer, as described previously (50). Platelet
counts were measured using a Coulter counter (model ZM) and
adjusted to 150,000/
 
m
 
l by the addition of buffer.
 
Adhesion Assays.
 
Adherent cells were assayed by colorimetry
(45, 51) or by loading THP-1 or 293 cells and thioglycollate-elic-
ited murine neutrophils with BCECF AM (1 
 
m
 
M) according to
the manufacturer’s protocol. Cells (10
 
5
 
/well) were placed in 96-
well microtiter plates coated with purified GP Ib
 
a
 
 (10 
 
m
 
g/ml) or
fibrinogen (10 
 
m
 
g/ml) and blocked with gelatin (0.2%). Adhesion
was stimulated with PMA (17 ng/ml) or the 
 
b
 
2-stimulating mAb
KIM 127 (5 
 
m
 
g/ml). Plates were washed with 0.9% NaCl (three
to five times), adherent cells were fixed in methanol for 15 min
and stained with Giemsa, and adhesion was quantified by measur-
ing absorbance at 540 nm. Alternatively, adhesion was quantified
by measuring the fluorescence of BCECF AM–loaded cells using
a Cytofluor II fluorescence multiwell microplate reader (PerSep-
tive Biosystems). The effect of anti-CD11/CD18 mAbs or solu-
ble Mac-1 ligands (i.e, fibrinogen, heparin) on adhesion was as-
sessed by preincubating cells with the indicated mAb (10 
 
m
 
g/ml)
or ligand for 15 min at 37
 
8
 
C; the effect of anti-GP Ib
 
a
 
 mAbs on
adhesion was investigated by incubating the indicated mAb (10
 
m
 
g/ml) with GP Ib
 
a
 
–coated wells for 30 min at 37
 
8
 
C before the
addition of cells. Data are expressed as percent inhibition of max-
imum adherent responses of respective sets of treatment.
In the case of 293 cell adhesion experiments, low passage (1 to
3) human saphenous vein endothelial cells (provided by Dr. Peter
Libby, Brigham and Women’s Hospital) were grown to conflu-
ence in 96-well microtiter wells and stimulated with TNF-
 
a
 
 (10
ng/ml) for 4 h to upregulate ICAM-1 expression (52). 293 cells
were loaded with BCECF AM for 45 min at 37
 
8
 
C, washed, and
stimulated with KIM 127 (5 
 
m
 
g/ml) before adding to endothelial
cell monolayers.
 
Purified I Domain Binding Experiments.
 
High-binding microti-
ter plates (MaxiSorp; Nunc) were coated with purified I domain
(10 
 
m
 
g/ml), obtained as described previously (38), in Tris-buf-
fered saline (TBS), pH 7.4, and then blocked with buffer contain-
ing 0.5% gelatin. Biotinylated glycocalicin (0–50 mg/ml) was
added to each well in TBS containing 1 mM CaCl2 and MgCl2
and 0.5% gelatin, and plates were incubated for 60 min at 258C.
After washing, bound glycocalicin was quantified with avidin
peroxidase. Specific binding was determined by subtracting bind-
ing to wells coated with gelatin alone and accounted for up to
40% of the total binding.
Neutrophil Adhesion to Surface-adherent Platelets. Neutrophil
adhesion to surface-adherent platelets was investigated as de-
scribed previously (12). Gel-filtered human platelets (z1.5  3
107) were added to 96-well microtiter plates coated overnight
with 0.2% gelatin. After 45 min at 378C, unbound platelets were
removed by washing. Neutrophils (1.5 3 105) were loaded with
Figure 1. Purified glycocalicin. Puri-
fied glycocalicin from human platelets
was subjected to SDS and 7.5% PAGE
and stained with Coomassie brilliant blue.196 GP Iba Is a Counterreceptor for Mac-1
1 mM BCECF AM, washed twice, and then added to each well
for 60 min at 378C in 5% CO2. After washing, neutrophil adhe-
sion was quantified as the percentage of total cells adherent by
measuring the fluorescence of BCECF AM–loaded cells using a
Cytofluor II fluorescence multiwell microplate reader (PerSep-
tive Biosystems). Fluorescence of input neutrophils before wash-
ing served as a measure of total cell number. The effect of mAbs
on neutrophil adhesion to platelets was assessed as described
above for purified GP Iba; the effect of the snake venom metal-
loprotease, mocarhagin, which cleaves GP Iba at peptide bond
282–283 (35), on leukocyte adhesion to platelets was examined
by preincubating surface-adherent platelets with mocarhagin for
30 min at 378C. Data are expressed as percent inhibition of max-
imum adherent responses of respective sets of treatment.
Whole Blood Detection of Platelet–Leukocyte Aggregates. Leuko-
cyte–platelet aggregates were measured by two-color flow cy-
tometry in a FACSCalibur™ flow cytometer (Becton Dickinson)
by slight modifications of methods described previously (19). Pe-
ripheral blood was drawn from a healthy volunteer or, as indi-
cated, from a patient with Bernard-Soulier syndrome (BSS) (53)
who had not ingested aspirin or other antiplatelet drugs during
the previous 10 d. The first 2 ml of drawn blood was discarded.
Blood was then drawn into a 3.2% sodium citrate Vacutainer
(Becton Dickinson). The sample was diluted 1:1 with modified
Tyrode’s Hepes buffer, pH 7.4, and then immediately incubated
at 228C for 10 min with either (a) buffer alone; (b) 0.5 mM ADP
(Biodata); or (c) 5 mM thrombin receptor activating peptide
(TRAP; 14-mer; Calbiochem) and saturating concentrations of
Y2/51-FITC and TUK4-PE. The samples were then fixed at
228C for 10 min to a final concentration of 1% formalin (Poly-
sciences, Inc.) and 1.53 HBSS concentrate (GIBCO BRL). The
samples were then diluted with 500 ml of distilled H2O, vor-
texed, and incubated at 228C for 10 min to lyse the red blood
cells. Monocytes and neutrophils were identified by CD14-PE
positivity and their characteristic light scatter.
THP-1 Adhesion to Glycocalicin under Flow. The interaction of
TGF-b1/vit D3–stimulated THP-1 cells with immobilized gly-
cocalicin was examined using a parallel-plate flow chamber sys-
tem, which has been described previously (54). Glass coverslips,
which form the bottom of the chamber, were coated with puri-
fied glycocalicin (100 mg/ml) by immersing them in the glyco-
calicin solution for 3 h at 378C. Residual nonspecific binding
sites were then blocked with 3% BSA for 30 min. The chamber
was then assembled and mounted onto an inverted-stage micro-
scope (DIAPHOT-TMD; Nikon) equipped with a silicon-inten-
sified target video camera (model C2400; Hammatus) connected
to a video cassette recorder. Cells were suspended in culture me-
dium and the suspension was brought to room temperature. 1 ml
of the cell suspension (106 cells/ml) was then injected into the
chamber and incubated for 1 min. The cells were allowed to set-
tle onto the glycocalicin substrate for 1 min; the chamber was
then perfused with the PBS at a flow rate calculated to generate
fluid shear stress of 2 dyn/cm2. The attachment and rolling of
cells in a single-view field were recorded in real time for 3 min,
and the video data were then analyzed using imaging software
(IC-300 Modular Image Processing Workstation; Inovision
Corp.) to calculate the rolling velocities. The rolling events
scored were ligand specific as confirmed in parallel determina-
tions on control substrates coated with heat-stable antigen (HSA).
In the study to inhibit glycocalicin, the coverslip was incubated
with the GP Iba mAb VM16d (25 mg/ml) for 30 min at room
temperature and washed before assembly of the chamber. To test
the effect of Mac-1 inhibition, the THP-1 cells were incubated
with LMP19c (25 mg/ml) for 30 min at room temperature before
injection into the chamber. Rolling cells were those observed to
be moving in the direction of flow while maintaining constant
contact with the glycocalicin substrate.
Statistics. All data are presented as the mean 6 SD. Groups
were compared using the nonpaired t test. P values , 0.05 were
considered significant.
Results
Mac-1–expressing Cells Bind to GP Iba. Given the ho-
mology between the receptor-binding vWf A1 domain and
the Mac-1 I domain, we hypothesized that Mac-1 would
bind the platelet GP Ib-IX-V complex. To assess this po-
tential interaction, we assayed the adhesion of Mac-1–bear-
ing cells to purified glycocalicin, the soluble extracellular
domain of GP Iba. We have previously shown that stimu-
lation of THP-1 monocytic cells (which constitutively ex-
Figure 2. THP-1 cell adhesion to GP Iba is Mac-1 dependent. Cy-
tokine-treated THP-1 cells were added to glycocalicin (GP Iba)–coated
and gelatin-blocked wells. Adhesion was promoted by the addition of the
stimulating mAb KIM 127 (5 mg/ml). The effect of anti-CD18 (IB4),
anti-CD11a (TS1/22), and anti-CD11b (LPM19c) mAbs on adhesion
was assessed as described in Materials and Methods. After washing, (A)
adherent cells were stained with Giemsa and (B) adhesion was quantified
by measuring the fluorescence of BCECF AM–loaded THP-1 cells.
Triplicate determination (mean 6 SD) representative of three to five sep-
arate experiments.197 Simon et al.
press Mac-1) with TGF-b1 and 1,25-(OH)2 vitamin D3 in-
creases Mac-1 surface expression z2.0-fold (45). When
cytokine-treated THP-1 cells were stimulated with either
phorbol ester (PMA) or KIM 127, an mAb to CD18 that
induces a change in the conformation of CD18 and pro-
motes both LFA-1– and Mac-1–dependent adhesion (40),
they adhered robustly to wells coated with GP Iba and
blocked with gelatin, but not to wells coated with gelatin
alone (Fig. 2). Adhesion of the cells to GP Iba was inhib-
ited by IB4, an anti-CD18 mAb that blocks both LFA-1–
and Mac-1–dependent functions, indicating that adhesion
is CD18 dependent (Fig. 2, and Table I). THP-1 cell adhe-
sion to GP Iba was also completely blocked by LPM19c,
an mAb that binds to the I domain of the aM subunit of
Mac-1 (CD11b) and blocks the binding of fibrinogen,
C3bi, and ICAM (24). In contrast, the anti–LFA-1 mAb
TS1/22 had no effect on adhesion. Similar results were ob-
tained with integrin mAbs whether THP-1 cell adhesion
was stimulated with KIM 127 or PMA, ruling out the pos-
sibility that the mAbs inhibited adhesion by interfering
with the binding of KIM 127 to CD18.
To confirm that Mac-1 mediates the adhesion of THP-1
cells to GP Iba and to eliminate the possibility that mAbs
to Mac-1 inhibit THP-1 cell adhesion indirectly, we as-
sessed the adhesion of 293 cells transfected with either
LFA-1 or Mac-1 to GP Iba. Flow cytometry confirmed
similar expression levels of LFA-1 and Mac-1 (Fig. 3 A).
Both LFA-1–transfected and Mac-1–transfected 293 cells
adhered robustly to human endothelial cells expressing
ICAM-1 (Fig. 3 B), indicating that these transfected 293
cells are functional. Mac-1–expressing 293 cells adhered to
GP Iba, and this adhesion was enhanced by KIM 127 (Fig.
3 C). KIM 127–stimulated adhesion was blocked by mAbs
directed to both CD11b and CD18, and to GP Iba
(VM16d). Neither untransfected 293 cells nor LFA-1–
transfected 293 cells bound to GP Iba.
Neutrophil Binding to GP Iba Requires Mac-1. To inves-
tigate further the role of Mac-1 in leukocyte adhesion to
GP Iba, we examined the binding of neutrophils from
wild-type (Mac-11/1) and Mac-1–deficient (Mac-12/2)
mice to GP Iba. Mac-11/1 neutrophils bound to GP Iba,
adhesion that was enhanced by PMA pretreatment (Fig. 4).
In contrast, Mac-12/2 neutrophils showed significantly re-
duced adhesion to GP Iba, whether in the absence or pres-
ence of PMA. Taken together, these observations indicate
that Mac-1 mediates adhesion to purified GP Iba.
The Mac-1 I Domain Serves as a Recognition Site for GP Iba.
The adhesion of Mac-1–bearing THP-1 cells to GP Iba
was inhibited by LPM19c (Fig. 2), an mAb that binds to
the I domain of the aM subunit of Mac-1 (CD11b). To
establish definitively that the Mac-1 I domain serves as a
recognition site for GP Iba, we transfected 293 cells with a
chimeric LFA-1 receptor that contained the I domain of
Mac-1 (i.e., LFA-1 [IaM]–transfected 293 cells). Flow cy-
tometry showed comparable expression of LFA-1 (IaM),
LFA-1, and Mac-1 in transfected 293 cells (Fig. 3 A). LFA-
1–transfected 293 cells did not adhere to GP Iba (Fig. 3 C);
in contrast, LFA-1 (IaM)–transfected 293 cells adhered ro-
bustly to GP Iba (Fig. 5 A), indicating that the I domain of
Mac-1 is required for adhesion to GP Iba. We next inves-
tigated whether GP Iba would directly bind to purified I
domain of Mac-1. Biotinylated glycocalicin bound to im-
mobilized I domain in a concentration-dependent manner
over the range 0–200 nM (Fig. 5 B).
To evaluate further the I domain as a recognition site on
Mac-1 for GP Iba, we examined the ability of Mac-1 I do-
main ligands (e.g., fibrinogen [24] and heparin [4]) to in-
hibit THP-1 adhesion to GP Iba. Soluble fibrinogen (50%
inhibitory concentration [IC50] z 1 mM) and heparin (IC50
z 75 U/ml) both inhibited adhesion in a dose-dependent
manner (Fig. 6, A–C). Inhibition by fibrinogen suggested
to us the possibility that the GP Iba and fibrinogen binding
sites in Mac-1 may be partially overlapping. To exclude
Table I. Summary of Inhibition of KIM 127–stimulated THP-1 
Adhesion to GP Iba by Antibodies or Soluble Ligands
Antibody or ligand Receptor (epitope)
Percent
inhibition
IB4 Anti-CD18 99 6 1*
TS1/22 Anti-CD11a (I domain) 10 6 13
LPM19c Anti-CD11b (I domain) 92 6 12*
Polyclonal Anti-GP Iba 80 6 17*
Polyclonal Rabbit IgG control 16 6 20
VM16d Anti-GP Iba
(aa residues 201–268) 83 6 16*
AP1 Anti-GP Iba
(aa residues 201–268) 86 6 10*
AK2 Anti-GP Iba
(aa residues 36–59) 16 6 6
SZ2 Anti-GP Iba (sulfated
tyrosine residues 269–282) 8 6 6
WM23 Anti-GP Iba
(macroglycopeptide) 11 6 5
7E3 Anti-GP IIb-IIIa,
-avb3, –Mac-1 16 6 8
10E5 Anti-GP IIb-IIIa 18 6 6
Fibrinogen (2 mM) Mac-1 99 6 1*
P2g377–395 (10 mM) Mac-1 0
Heparin (200 U/ml) Mac-1 93 6 9*
vWF A1 (20 mg/ml) GP Iba 83 6 13*
The adhesion of cytokine-treated THP-1 cells to glycocalicin (GP Iba)–
coated microtiter wells was stimulated by the addition of KIM 127 (5
mg/ml) in the presence and absence of antibodies directed to or soluble
ligands of Mac-1 and GP Iba. Polyclonal antibodies were added at 20
mg/ml and purified mAbs at 10 mg/ml as described in Materials and
Methods. Soluble ligand concentrations are indicated. CD11/CD18
mAbs included IB4, TS1/22, and LPM19c; GP Iba mAbs used were
AK2, AP1, VM16d, SZ2, and WM23. Data are expressed as percent
inhibition of maximal KIM-stimulated adhesion by the antibodies or
soluble ligands (mean 6 SD, n 5 3–5). aa, amino acids.
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binding (IC50 z 1 mM) (38). P2 had no effect on THP-1
adhesion to GP Iba, suggesting that the GP Iba and fibrin-
ogen binding sites are probably distinct.
To evaluate the interaction between Mac-1 and GP Iba
more quantitatively and to confirm that Mac-1 did not rec-
ognize a binding site present solely on immobilized GP
Iba, we tested soluble GP Iba for its ability to inhibit Mac-
1–dependent THP-1 cell adhesion to immobilized GP Iba
(Fig. 6 B) or fibrinogen (Fig. 6 C). Soluble GP Iba inhib-
ited THP-1 adhesion to wells coated with either GP Iba
(IC50 5 0.5 mM) or fibrinogen (IC50 5 0.25 mM). Con-
versely, the vWf A1 domain (20 mg/ml), a ligand for GP
Iba, blocked binding of THP-1 cells to immobilized GP
Iba (percent inhibition 5 83 6 13) (Table I).
Identifying the Mac-1 Binding Site within GP Iba. We
next turned our attention to identifying the Mac-1 interac-
tion site within GP Iba by assessing the effect of mono-
clonal and polyclonal antibodies to GP Iba on Mac-1–
dependent THP-1 cell adhesion to glycocalicin (Fig. 7, and
Table I). Polyclonal anti–GP Iba, but not control rabbit
IgG, significantly reduced THP-1 cell adhesion. VM16d
and AP1, which map to the leucine-rich COOH-terminal
flanking region of GP Iba (amino acids 201–268), inhib-
ited KIM 127–stimulated adhesion of THP-1 cells to GP
Figure 3. Mac-1 expression is required
for adhesion to GP Iba. (A) Expression of
CD11/CD18 integrin in 293 cells was con-
firmed by flow cytometry using the anti-
CD18 mAb IB4. Equivalent expression of
CD18 is observed in 293 cells transfected
with human LFA-1, Mac-1, or a chimeric
LFA-1 containing the I domain of Mac-1,
designated LFA-1 (IaM). (B) Adhesion of
untransfected 293 cells and 293 cells trans-
fected with human Mac-1 or LFA-1 to hu-
man endothelial cells stimulated with TNF-a
to express ICAM-1. Adhesion was pro-
moted by the addition of the stimulating
mAb KIM 127 (5 mg/ml) and quantified by
measuring the fluorescence of BCECF
AM–loaded 293 cells; triplicate determina-
tion (mean 6 SD) representative of two
separate experiments. (C) 293 cells were
added to glycocalicin-coated and gelatin-
blocked wells. Adhesion was promoted by
the addition of KIM 127 (5 mg/ml). After
washing, adherent cells were stained with
Giemsa. Triplicate determination represen-
tative of three separate experiments.
Figure 4. Neutrophil binding to GP Iba requires Mac-1. Thioglycol-
late-elicited neutrophils from wild-type (Mac-11/1) or Mac-1–deficient
(Mac-12/2) mice were added to glycocalicin-coated and gelatin-blocked
wells in the absence (black bars) and presence (white bars) of PMA (17
ng/ml). Adhesion was promoted by the addition of PMA (17 ng/ml).
Adhesion was quantified by measuring the fluorescence of BCECF AM–
loaded neutrophils. Triplicate determination (mean 6 SD) representative
of three separate experiments.
potential nonspecific steric hindrance of fibrinogen, we ex-
amined the effect of peptide P2, corresponding to amino
acid residues 377–395 in the g chain of fibrinogen, that
binds to the I domain of Mac-1 and blocks fibrinogen199 Simon et al.
Iba (percent inhibition: VM16d 5 83 6 16; AP1 5 86 6
10). A similar inhibitory effect of these mAbs was noted
when THP-1 cell adhesion to GP Iba was stimulated by
PMA (percent inhibition: VM16d 5 90 6 4; AP1 5 84 6
2). In contrast, neither AK2, directed to the first leucine-
rich repeat (amino acids 36–59), nor WM23, directed to
the macroglycopeptide mucin core region of GP Iba, had
any significant effect on THP-1 cell adhesion. An irrelevant
mAb against GP IIb-IIIa (10E5) also had no significant ef-
fect on THP-1 cell adhesion.
Our observation that heparin inhibited Mac-1–dependent
adhesion to GP Iba led us to consider the possibility that the
region within GP Iba containing sulfated tyrosine residues
(an anionic stretch between residues Asp269 and Asp289
which contains three sulfated tyrosines, Tyr276, Tyr278,
and Tyr279) might be involved in the interaction with Mac-1.
We tested this possibility by assessing the effect of SZ2, an
anti-GP Iba mAb that maps within the region containing
the sulfated tyrosines and requires sulfation for its epitope.
SZ2 did not affect THP-1 cell adhesion to GP Iba, suggest-
ing that heparin likely inhibits adhesion by binding the Mac-1
I domain and interfering with GP Iba binding rather than
by directly mimicking a binding site on GP Iba (4).
Glycocalicin Supports the Rolling and Firm Adhesion of THP-1
Cells under Flow. To evaluate the potential for the GP
Iba–Mac-1 interaction to support the adhesion of blood
cells under flow, we perfused THP-1 cells over coverslips
coated with a glycocalicin matrix using a parallel-plate flow
chamber system. The cells were either kept in their native
state or treated with TGF-b1 and 1,25-(OH)2 vitamin D3
to increase Mac-1 expression. THP-1 cells were able to ad-
here to the glycocalicin, whether or not they were induced
to differentiate, but did not adhere to control, BSA-coated
coverslips (Fig. 8). However, undifferentiated cells that ad-
hered to the glycocalicin exhibited mainly rolling behavior,
whereas differentiated cells adhered more firmly. The anti-
bodies LMP19c and VM16d both greatly decreased the
number of attached cells, confirming the involvement of
both Mac-1 and GP Iba, respectively, in the adhesion of
THP-1 cells under flow.
Mac-1 and GP Iba Facilitate the Interaction between Leuko-
cytes and Platelets. Finally, to establish that Mac-1 and GP
Iba facilitate the heterotypic interaction between leuko-
cytes and platelets, we assayed the adhesion of wild-type
and Mac-1–deficient neutrophils to platelets. Thioglycol-
late-elicited Mac-11/1 neutrophils bound to adherent
Figure 5. Mac-1 I domain serves as a recognition site for GP Iba. (A)
293 cells transfected with human Mac-1, LFA-1, or a chimeric LFA-1
containing the I domain of Mac-1 (LFA-1 [IaM]) were added to glyco-
calicin-coated and gelatin-blocked wells. Adhesion was promoted by the
addition of the stimulating mAb KIM 127 (5 mg/ml) and quantified by
measuring the fluorescence of BCECF AM–loaded 293 cells. Triplicate
determination (mean 6 SD) representative of three separate experiments.
(B) Interaction of purified glycocalicin and Mac-1 I domain. Specific
binding of biotinylated glycocalicin (0–200 nM) to purified I domain–
coated and gelatin-blocked wells as described in Materials and Methods
(B). Triplicate determination (mean 6 SD), n 5 2.
Figure 6. Mac-1–GP Iba
binding and Mac-1 I domain
ligands. Cytokine-treated THP-1
cells were added to (A) glyco-
calicin-coated or (B) fibrinogen
(FGN)-coated wells. Adhesion
was promoted by the addition of
KIM 127 (5 mg/ml) in the pres-
ence of increasing concentrations
(0–2 mM) of soluble GP Iba (s)
or the soluble Mac-1 I domain
ligand fibrinogen (j). (C) The
adhesion of THP-1 cells to gly-
cocalicin (GP Iba)–coated wells
in the presence of increasing
concentrations of a second Mac-1
I domain ligand, heparin (0–100
U/ml), was also examined. Ad-
hesion was quantified by mea-
suring the fluorescence of
BCECF AM–loaded cells and
expressed relative to maximal ad-
hesion stimulated with KIM 127.
Mean 6 SD, n 5 3.200 GP Iba Is a Counterreceptor for Mac-1
platelets, and this adhesion was promoted by PMA (Fig. 9
A). In contrast, Mac-12/2 neutrophils demonstrated mark-
edly reduced adhesion to platelets. Adhesion of Mac-11/1
neutrophils was also blocked by the rat anti–mouse Mac-1
mAb M1/70 (percent inhibition 5 95 6 5) and the anti-
GP Iba mAb VM16d (percent inhibition 5 55 6 10). Fur-
thermore, Mac-11/1 leukocyte adhesion to platelets was
inhibited dose-dependently by soluble glycocalicin (per-
cent inhibition 5 72 6 18) and by pretreatment of adher-
ent platelets with the snake venom metalloprotease, mocar-
hagin (percent inhibition 5 89 6 8), which cleaves GP Iba
at peptide bond 282–283 as the only detectable proteolytic
event on the platelet surface (35) (Fig. 9 B). Taken to-
gether, these observations indicate that neutrophil adhesion
to platelets is primarily mediated by Mac-1 and GP Iba.
Finally, to provide additional evidence supporting a role
for GP Iba in platelet binding to leukocytes, we assessed
the presence of leukocyte–platelet aggregates in whole
blood obtained from a normal volunteer or a patient with
BSS. We have previously shown that spontaneous or ago-
nist-induced leukocyte–platelet aggregate formation re-
quire an interaction between P-selectin glycoprotein ligand
1 (PSGL-1) and P-selectin that is strengthened by integrins
(19). Leukocyte–platelet aggregates were decreased in the
circulation of a patient with BSS compared with a normal
control (2 vs. 7% platelet-positive neutrophils; Fig. 10).
Moreover, these leukocyte–platelet aggregates were less
likely to form in the BSS patient after agonist stimulation
with either 0.5 mM ADP (4 vs. 21% platelet-positive neu-
trophils) or 5 mM TRAP (13 vs. 86% platelet-positive neu-
trophils). Mac-1 dependence in leukocyte–platelet aggre-
gate formation in this assay was confirmed by the fact that
the anti–Mac-1 mAb LPM19c completely inhibited ago-
nist-induced platelet–neutrophil complex formation.
Discussion
In this study, we have identified a direct interaction be-
tween the leukocyte integrin Mac-1 and platelet GP Iba.
The following evidence was obtained for this interaction:
(a) mAbs to both Mac-1 and GP Iba inhibited THP-1 cell
Figure 7. Epitope map of mAbs to GP Iba. Schematic representation
of the extracellular domain of GP Iba. The GP Iba mAbs employed
were: AK2, AP1, VM16d, SZ2, and WM23. AK2 binds within the first
leucine-rich repeat (amino acid residues 36–58). AP1 and VM16d bind to
the COOH-terminal flanking and leucine-rich repeat region (201–268).
SZ2 maps to the sulfated tyrosine residues encompassing amino acids
268–282 (reference 41). WM23 binds within the macroglycopeptide re-
gion of GP Iba (reference 42).
Figure 8. Adhesion of THP-1 cells to glycocalicin under flow. (A) Video images of THP-1 cells rolling on or firmly adherent to immobilized glycocali-
cin at a wall shear stress of 2 dyn/cm2 in a parallel-plate flow chamber. Images were created using a digital image processing system to snap frames of pre-
viously recorded experiments. The cells were either untreated (Undifferentiated) or induced to differentiate with TGF-b1 and 1,25-(OH)2 vitamin D3
then injected into the chamber and allowed to settle on the matrix for 1 min. The chamber was then perfused with buffer at a velocity calculated to gen-
erate the desired shear stress. Images were created by overlapping 30 frames taken over 1 s. The effect of mAbs VM16d (anti-GP Iba) and LMP19c (anti-
CD11b) were assessed by preincubating, respectively, either the coverslip or the cells with saturating concentrations of antibody. BSA-coated coverslips
were used as a control matrix. (B) Quantitation of rolling and firmly adherent cells from experiments such as those represented in A (mean 6 SEM, n 5 4).201 Simon et al.
adhesion to purified GP Iba; (b) 293 cells that express
Mac-1, but not LFA-1, bound strongly to GP Iba, and this
adhesion was inhibited specifically by mAbs; (c) wild-type,
but not Mac-1–deficient, neutrophils adhered to platelets
and to purified GP Iba; (d) neutrophil adhesion to platelets
was inhibited by mAbs to Mac-1 and GP Iba and by pre-
treatment of the platelets with the snake venom metallo-
protease, mocarhagin, whose major platelet substrate is GP
Iba (35); and (e) basal and agonist-stimulated leukocyte–
platelet aggregates were decreased in whole blood of a pa-
tient with BSS compared with a normal control.
By virtue of binding diverse ligands including, among
others, fibrin(ogen) (55, 56), ICAM-1 (57), factor X (58),
C3bi (55), high molecular weight kininogen (59), and hep-
arin (4), Mac-1 regulates important leukocyte functions
including adhesion, migration, coagulation, proteolysis,
phagocytosis, oxidative burst, and signaling (49, 60–62).
However, these ligands do not account for all of Mac-1’s
adhesive interactions. Although previous studies have
shown that Mac-1, the primary fibrin(ogen) receptor on
leukocytes, directly facilitates the recruitment of leukocytes
at sites of platelet and fibrin deposition (12–14), the precise
platelet counterreceptor was unidentified.
I or A domains are regions of z200 amino acids that are
present in 1 or more copies in many proteins involved in
cell–cell, cell–matrix, and matrix–matrix interactions (25,
31). This superfamily motif is present in integrin a sub-
units, including CD11a, CD11b, CD11c, CD11d, CD49a,
CD49b, and aE (25), the complement proteins Factors B
and C2 (63, 64), collagens (65, 66), and vWf (29). For
CD11b, experimental evidence supports the notion that
the I domain is responsible for the binding of all Mac-1
ligands except for factor X (24, 67). vWf has three similar
domains, in this case termed A domains. The first and third
of these, A1 and A3, mediate binding to GP Iba and col-
lagen, respectively (68). High-resolution crystal structures
of the CD11b I domain and the vWf A1 domain show that
both of these domains adopt a classic a/b “Rossman” fold
(25, 69). The Mac-1 I domain also contains a metal ion–
dependent adhesion site (MIDAS) for binding protein
ligands, a motif, however, not present in the vWf A1 do-
main due to the presence of an arginine and an alanine in-
stead of a serine and an aspartate, respectively, at two of the
critical amino acids forming the MIDAS motif. The obser-
vation that mutations of the aM I domain that correspond
to gain-of-function mutations of the vWf A1 domain also
alter the binding activity of Mac-1 (48) supports the notion
that Mac-1 and vWf may be functionally similar with re-
spect to GP Ib-IX-V binding.
The binding of GP Iba to vWf and Mac-1 has several
similarities and some interesting differences. First, as ex-
pected, the binding involves the homologous I or A do-
mains. In addition, in both cases binding requires a confor-
mational change of the A or I domain, in the case of vWf
requiring ristocetin, botrocetin, or shear stress, and in the
case of Mac-1 requiring activation of the integrin to its
ligand-competent form. Distinguishing the two interac-
tions is the distinct pattern of inhibition by GP Iba anti-
bodies. AK2, for example, is a potent inhibitor of vWf
binding to GP Iba, whether induced by ristocetin, botro-
cetin, or shear stress. This antibody failed to inhibit the in-
teraction of Mac-1 with GP Iba. VM16d, on the other
hand, does not inhibit vWf binding to GP Iba, except as
induced by botrocetin, but is a potent inhibitor of Mac-1
binding. However, the sites are not completely distinct, as
indicated by the observation that the isolated vWf A1 do-
Figure 9. Neutrophil binding to platelets requires Mac-1 and GP Iba.
(A) Thioglycollate-elicited neutrophils from wild-type (Mac-11/1, black
bars) or Mac-1–deficient (Mac-12/2, white bars) mice were added to sur-
face-adherent platelets. Adhesion was promoted by the addition of PMA
(17 ng/ml). The contribution of Mac-1 or GP Iba to wild-type neutro-
phil adhesion to platelets was assayed by the addition of the rat anti–
mouse CD11b mAb, M1/70 (10 mg/ml), or the anti-GP Iba mAb,
VM16d (10 mg/ml), respectively. (B) The effect of soluble glycocalicin
(0–20 mg/ml) and the snake venom metalloprotease, mocarhagin, which
cleaves GP Iba at peptide bond 282–283, on neutrophil adhesion was also
examined. Adhesion was quantified by measuring the fluorescence of
BCECF AM–loaded neutrophils. Triplicate determination (mean 6 SD)
representative of three separate experiments.
Figure 10. Absence of GP Iba
reduces neutrophil–platelet ag-
gregates in whole blood. Leuko-
cyte–platelet aggregates in periph-
eral blood obtained from a
normal volunteer (black bars) or a
patient with BSS (white bars)
were measured by two-color flow
cytometry as described in Materi-
als and Methods. Formation of
leukocyte–platelet aggregates was
stimulated by incubating blood with ADP (0.5 mM) or TRAP (5 mM).
Data shown are mean values of duplicate determinations.202 GP Iba Is a Counterreceptor for Mac-1
main blocks the interaction of Mac-1–expressing cells with
GP Iba and by the ability of the mAb AP1, which also
blocks ristocetin- and botrocetin-induced vWf binding, to
inhibit the interaction.
The identification of the interaction between GP Iba
and Mac-1 provides a tantalizing lead into the nature of
leukocyte–platelet adhesion, helping to clarify the sequen-
tial adhesion model of neutrophil attachment to surface-
adherent platelets proposed by Diacovo et al. (12). Never-
theless, our data do not rule out the possibility of additional
platelet surface receptors for Mac-1. Other potential Mac-1
ligands present on the platelet membrane include fibrino-
gen (bound to GP IIb-IIIa) (55, 56), ICAM-2 (70), high
molecular weight kininogen (59), and glycosaminoglycans
(4). A leukocyte–platelet interaction mediated by fibrino-
gen bridging between Mac-1 and GP IIb-IIIa has been dis-
counted by Ostrovsky et al. (22), who found that neither
RGDS peptides nor the replacement of normal platelets
with thrombasthenic platelets (i.e., lacking GP IIb-IIIa) af-
fected the accumulation of the leukocytes on platelets, and
recently by Furman et al. (71), who found that GP IIb-IIIa
antagonists and RGDS peptides did not reduce leukocyte–
platelet aggregate formation in whole blood.
Other interactions contributing to Mac-1–independent
leukocyte–platelet complex formation include thrombo-
spondin bridging between GP IV receptors on platelets and
monocytes (72), and P-selectin on activated platelets bind-
ing with leukocyte PSGL-1 (73, 74). Nevertheless, under
the experimental conditions employed in the present study,
which assayed the adhesion of activated neutrophils (i.e.,
thioglycollate-elicited peritoneal neutrophils) to surface-
adherent platelets after vigorous washing, the predominant
interaction between neutrophils and platelets appeared to
be between Mac-1 and GP Iba.
These present observations also suggest a possible target
for therapeutic intervention. In particular, the distinct differ-
ence in the inhibitory patterns of GP Iba antibodies suggests
that it might be possible to prevent leukocyte attachment to
platelets by targeting GP Iba without inhibiting platelet ad-
hesion to the vessel wall. Our recent observations have iden-
tified Mac-1 as a molecular determinant of neointimal thick-
ening after experimental arterial injury that produces
endothelial denudation and platelet and/or fibrin deposition.
We found that antibody-mediated blockade (7) or selective
absence (75) of Mac-1 impaired transplatelet leukocyte mi-
gration into the vessel wall, diminishing medial leukocyte
accumulation and neointimal thickening after experimental
angioplasty or endovascular stent implantation. Therefore,
future studies aimed at identifying the precise binding site(s)
responsible for Mac-1–GP Iba binding might provide a mo-
lecular strategy for disrupting leukocyte–platelet complexes
that promote vascular inflammation in thrombosis, athero-
sclerosis, and angioplasty-related restenosis.
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